Assignee
Ichnos Sciences SA
CH·10 granted patents·17 pending applications·16 citations·filing 2015–2025
Top patents by PatentIndex Score
27 records- 0194US11891454B2Production of T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2020·Granted Feb 6, 2024·3 cites·15 claims
- 0290US11970539B2Antibodies that bind to IL1RAP and uses thereofIchnos Sciences SA·Filed 2021·Granted Apr 30, 2024·4 cites·11 claims
- 0389US11773166B2CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their productionIchnos Sciences SA·Filed 2018·Granted Oct 3, 2023·5 cites·12 claims
- 0488US11851502B2Production of T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2018·Granted Dec 26, 2023·3 cites·13 claims
- 0582US11407839B2Antibodies that bind to OX40 and their usesIchnos Sciences SA·Filed 2019·Granted Aug 9, 2022·1 cites·30 claims
- 0681US12281169B2Antibodies that bind to OX40 and their usesIchnos Sciences SA·Filed 2022·Granted Apr 22, 2025·0 cites·28 claims
- 0777US2025250351A1Antibodies that bind to ox40 and their usesIchnos Sciences SA·Filed 2025·Application pending·0 cites
- 0876US2022213227A1T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2022·Application pending·0 cites
- 0976US2025059290A1Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseasesIchnos Sciences SA·Filed 2024·Application pending·0 cites
- 1072US12006367B2CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their productionIchnos Sciences SA·Filed 2022·Granted Jun 11, 2024·0 cites·9 claims
- 1167US2024002434A1Methods of inactivating viral contaminantsIchnos Sciences SA·Filed 2023·Application pending·0 cites
- 1266US2024059783A1Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disordersIchnos Sciences SA·Filed 2023·Application pending·0 cites
- 1363US2021214453A1Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseasesIchnos Sciences SA·Filed 2019·Application pending·0 cites
- 1460US11884700B2Methods of inactivating viral contaminantsIchnos Sciences SA·Filed 2020·Granted Jan 30, 2024·0 cites·14 claims
- 1557US2024228650A9CD3/BCMA/CD38 Trispecific AntibodiesIchnos Sciences SA·Filed 2023·Application pending·0 cites
- 1656US2024150489A1Cd47-cd38 bispecific antibodiesIchnos Sciences SA·Filed 2023·Application pending·0 cites
- 1756US2022081666A1Methods of cell culture clarificationIchnos Sciences SA·Filed 2019·Application pending·0 cites
- 1855US2024141062A1Cd47-cd38 bispecific antibodiesIchnos Sciences SA·Filed 2023·Application pending·0 cites
- 1955US2021206864A1Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disordersIchnos Sciences SA·Filed 2019·Application pending·0 cites
- 2053US12351602B2Methods of inactivating viral contaminantsIchnos Sciences SA·Filed 2018·Granted Jul 8, 2025·0 cites·12 claims
- 2141US2020347143A1Novel tnfr agonists and uses thereofIchnos Sciences SA·Filed 2017·Application pending·0 cites
- 2240US2024092903A1Antibody formulation diluentIchnos Sciences SA·Filed 2021·Application pending·0 cites
- 2338US10640564B2Antibodies that bind to CCR6 and their usesIchnos Sciences SA·Filed 2015·Granted May 5, 2020·0 cites·9 claims
- 2438US2022251138A1Processes for obtaining a highly concentrated antibody solutionIchnos Sciences SA·Filed 2020·Application pending·0 cites
- 2537US2023159661A1T cell redirecting bispecific antibodies for the treatment of egfr positive cancersIchnos Sciences SA·Filed 2018·Application pending·0 cites
- 2636US2022273796A1Lyophilized antibody formulationIchnos Sciences SA·Filed 2020·Application pending·0 cites
- 2733US2022177582A1Non-consensus glycosylation of bispecific antibodiesIchnos Sciences SA·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →